Healthcare Policy Lobbyist (Biotech)

About The Initiative

The Clinical Trial Abundance Initiative exists to reform federal policy and law governing clinical trials, making them faster, cheaper, and simpler to conduct. Founded by a coalition of leading science philanthropies, the initiative aims to leverage the 2027 reauthorization of the Prescription Drug User Fee Act (PDUFA) to enact real reform.

We draw on successful foreign models, such as Australia's notification-based trial pathway, to inform our efforts. This role is not focused on trial access, diversity, inclusion, or equity; instead, it seeks to change the rules governing clinical trials to increase their speed, affordability, and accessibility.

What This Role Is — And Isn't

This is a policy and law reform role, not an operations or access role. The work involves changing the rules governing clinical trials to enable more trials to be launched, run, and approved faster and at lower cost. Key responsibilities include:

• Serving as the initiative's lead voice with legislators, congressional staff, and agency officials, and with health-system and industry leaders.
• Shaping a substantive agenda to reform the policy and law around the cost, speed, and complexity of trials, and driving it into the PDUFA 2027 reauthorization and its implementation.
• Designing and building the coalition — recruiting and aligning companies, investors, research and patient organizations, and allied policymakers into a lasting interest group.
• Translating the scientific and regulatory case for reform into arguments that move different audiences, in partnership with the Chief Science Officer.
• Setting the initiative's strategy for the years beyond 2027, when the work shifts to field-building rather than chasing a single legislative deadline.

Requirements

• Deep credibility in biotech, life sciences, or FDA/clinical-trial policy — this is a subject-matter role, not a generalist government-affairs one.
• A track record of being taken seriously by senior, varied stakeholders: Hill offices, agencies, industry executives, investors, and researchers alike.
• Evidence that you can build something durable, not just win a near-term legislative fight — coalition-building, institution-building, or genuine 0→1 experience.
• Fluency in the case for reform that expands what's possible — cutting the friction, cost, and time between good science and the patients who need it.
• Nice to have: direct experience with PDUFA, user-fee reauthorizations, or FDA review-pathway reform; familiarity with international regulatory models (Australia, UK, EU); and an existing network spanning biotech, investors, research, and DC policy.

Benefits

• Competitive salary of $200,000 - $250,000 USD/year
• Private Health Insurance
• Paid Time Off
• Work From Home
• Training & Development